Full Press Release Details
Allarity Therapeutics Announces Adjournment
2023 Annual Meeting of Stockholders
Boston, MA U.S.A. (January 20, 2023) - Allarity
Therapeutics, Inc. ("Allarity" or the "Company"), a clinical-stage pharmaceutical company developing novel oncology
therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care today announced that the
Company's 2023 Annual Meeting of Stockholders (the "Meeting"), on January 19, 2023, at 1:00 p.m. (Eastern Time) was
adjourned without any business being conducted.
The Meeting was adjourned until Friday, February
3, 2023, to allow additional time for stockholders to vote on the proposals set forth in the Company's definitive proxy statement
filed with the U.S. Securities and Exchange Commission on December 6, 2022 (the "Proxy Statement").
The adjourned Meeting will reconvene on February
3, 2023, at 1:00 p.m. (Eastern Time) virtually at https://meetnow.global/MRJXJMN. The record date for the adjourned Meeting remains the
same, December 6, 2022. Stockholders of record may attend the virtual webcast meeting by logging in through the same method. During this
adjournment, the Company will continue to solicit votes from its stockholders regarding all proposals set forth in the Proxy Statement.
Stockholders who have already voted their shares on the proposals contained in the Proxy Statement do not need to vote again. Proxies
previously submitted will be voted at the adjourned Meeting, and stockholders who have previously submitted a proxy or otherwise voted
need not take any action.
Stockholders may use the Proxy Card that they
were originally provided with or vote in the manner as set forth in the Proxy Statement. Stockholders who have questions or require any
assistance in voting their shares may contact the Company at investorrelations@allarity.com.
Allarity encourages all stockholders, as of the
record date on December 6, 2022, who have not yet voted to do so promptly.
Allarity Therapeutics, Inc. | 24 School Street, 2nd Floor | Boston, MA | U.S.A. | NASDAQ: ALLR | www.allarity.com
About Allarity Therapeutics
Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops
drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology, the DRP
platform. The Company has a mature portfolio of three drug candidates: stenoparib, a PARP inhibitor in Phase 2 development for ovarian
cancer; dovitinib, a post-Phase 3 pan-tyrosine kinase inhibitor; and the European rights to IXEMPRA (Ixabepilone), a microtubule
inhibitor approved in the U.S. and marketed by R-PHARM U.S. for the treatment of second-line metastatic breast cancer, currently in Phase
2 development in Europe for the same indication. Additionally, the Company has rights in two secondary assets: 2X-111, a liposomal formulation
of doxorubicin for metastatic breast cancer and/or glioblastoma multiforme (GBM), which is the subject of discussions for a restructured
out-license to Smerud Medical Research International AS; and LiPlaCis , a liposomal formulation of cisplatin and its accompanying
DRP , being developed via a partnership with Chosa Oncology AB for late-stage metastatic breast cancer. The Company is
headquartered in the United States and maintains an R&D facility in Hoersholm, Denmark. For more information, please visit the Company's
website at www.Allarity.com.
About the Drug Response Predictor - DRP
Companion Diagnostic
Allarity uses its drug-specific DRP
to select those patients who, by the genetic signature of their cancer, are found to have a high likelihood of responding to the specific
drug. By screening patients before treatment, and only treating those patients with a sufficiently high DRP score, the
therapeutic response rate can be significantly increased. The DRP method builds on the comparison of sensitive vs. resistant
human cancer cell lines, including transcriptomic information from cell lines combined with clinical tumor biology filters and prior clinical
trial outcomes. DRP is based on messenger RNA from patient biopsies. The DRP platform has proven its ability
to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in 37 out of 47 clinical
studies that were examined (both retrospective and prospective), including ongoing, prospective Phase 2 trials of Stenoparib and IXEMPRA .
The DRP platform, which can be used in all cancer types and is patented for more than 70 anti-cancer drugs, has been extensively
published in peer reviewed literature.
Follow Allarity on Social Media
Facebook: https://www.facebook.com/AllarityTx/
Twitter: https://twitter.com/allaritytx
Allarity Therapeutics, Inc. | 24 School Street, 2nd Floor | Boston, MA | U.S.A. | NASDAQ: ALLR | www.allarity.com
Forward-Looking Statements
This press release contains "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide Allarity's
current expectations or forecasts of future events. The words "anticipates," "believe," "continue,"
"could," "estimate," "expect," "intends," "may," "might," "plan,"
"possible," "potential," "predicts," "project," "should," "would"
and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not
forward-looking. These forward-looking statements include, but are not limited to, statements related to clinical and commercial potential
due to the Company advancing dovitinib in combination with another therapeutic candidate or other approved drug, any statements related
to ongoing clinical trials for stenoparib as a monotherapy or in combination with another therapeutic candidate for the treatment of advanced
ovarian cancer, or ongoing clinical trials (in Europe) for IXEMPRA for the treatment of metastatic breast cancer, and
statements relating to the effectiveness of the Company's DRP companion diagnostics platform in predicting whether
a particular patient is likely to respond to a specific drug. Any forward-looking statements in this press release are based on management's
current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include,
but are not limited to, the risk that results of a clinical study do not necessarily predict final results and that one or more of the
clinical outcomes may materially change following more comprehensive reviews of the data, and as more patient data become available, the
risk that results of a clinical study are subject to interpretation and additional analyses may be needed and/or may contradict such results,
the receipt of regulatory approval for dovitinib or any of our other therapeutic candidates or, if approved, the successful commercialization
of such products, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product
candidates, the risk that the results of previously conducted studies will not be repeated or observed in ongoing or future studies involving
our therapeutic candidates, and the risk that the current COVID-19 pandemic will impact the Company's current and future clinical
trials and the timing of the Company's preclinical studies and other operations. For a discussion of other risks and uncertainties,
and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements,
see the section entitled "Risk Factors" in our Form S-1 registration statement on file with the Securities and Exchange Commission,
available at the Securities and Exchange Commission's website at www.sec.gov, and as well as discussions of potential risks, uncertainties
and other important factors in the Company's subsequent filings with the Securities and Exchange Commission. All information in
this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by
Allarity Therapeutics, Inc. | 24 School Street, 2nd Floor | Boston, MA | U.S.A. | NASDAQ: ALLR | www.allarity.com
Senior V.P. of Investor Relations
Carrotize PR & Communications
Allarity Therapeutics, Inc. | 24 School Street, 2nd Floor | Boston, MA | U.S.A. | NASDAQ: ALLR | www.allarity.com